Cyclosporine then low-dose immune therapy for new type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This Phase 2 study tests whether starting with cyclosporine and then giving low-dose IL-2 can better protect the body’s insulin-producing function after type 1 diabetes is diagnosed. It’s meant for people diagnosed very recently who have specific diabetes-related immune markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 45 years old (must be fully developed—Tanner stage 5).
- You were diagnosed with type 1 diabetes within the last 3 months and have at least one diabetes autoantibody (like GAD, IA-2, or ZnT8).
- You cannot have diabetic ketoacidosis (“acid ketosis”) or have lost more than 10% of body weight (or you must meet a specific C-peptide level after starting insulin).
- Your blood, liver, kidney, thyroid tests, and other basic safety tests must be normal enough to join.
- You must not have certain heart problems (and you need a normal ECG), and you must not be pregnant or breastfeeding.
- You cannot have specific infections (like HIV, hepatitis B/C, or high EBV/CMV levels), cancer within the last 5 years, major immune/organ contraindications, or recent use of diabetes drugs other than insulin for over 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This Phase 1/2 study tests whether CELZ-201 is safe and can help the body keep making some of its own insulin in people who were recently diagnosed with type 1 diabetes. You may be eligible if your diabetes started within the past year and your tests show you still have some insulin-making activity.
This study looks at children who have just started insulin for new-onset type 1 diabetes. It aims to test an intervention early in the course of the disease, which may help change how the immune system and diabetes progress.
This early-stage trial tests a combination approach to help your immune system stop attacking insulin-producing cells in newly diagnosed type 1 diabetes. It aims to preserve your body's ability to make insulin and slow disease progression.
This Phase 1 study tests a new immune-system strategy around islet transplantation (or donor bone marrow therapy) to improve control of type 1 diabetes and reduce dangerous low blood sugar. It mainly aims to see if the approach is safe and helpful in people with long-standing, difficult-to-manage diabetes.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.